{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:30:41Z","timestamp":1783402241028,"version":"3.54.6"},"reference-count":46,"publisher":"Elsevier BV","issue":"49","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.vaccine.2012.09.032","type":"journal-article","created":{"date-parts":[[2012,9,26]],"date-time":"2012-09-26T05:47:14Z","timestamp":1348638434000},"page":"7123-7129","source":"Crossref","is-referenced-by-count":46,"title":["Autoimmune disorders after immunisation with Influenza A\/H1N1 vaccines with and without adjuvant: EudraVigilance data and literature review"],"prefix":"10.1016","volume":"30","author":[{"given":"Alina","family":"Isai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Le Meur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Hidalgo-Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Kurz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2012.09.032_bib0005","unstructured":"Pandemic influenza A(H1N1)v vaccines authorised via the core dossier procedure. Explanatory note on scientific considerations regarding the licensing of pandemic A(H1N1)v vaccines. EMEA\/608259\/2009 rev. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Medicine_QA\/2009\/11\/WC500007567.pdf [accessed 05.07.11]."},{"key":"10.1016\/j.vaccine.2012.09.032_bib0010","unstructured":"WHO. Statement from WHO Global Advisory Committee on Vaccine Safety about the safety profile of pandemic influenza A(H1N1) 2009 vaccines. Available at: http:\/\/www.who.int\/vaccine_safety\/GACVS_H1N1_Vaccine_Safety.pdf [accessed 11.01.12]."},{"issue":"12","key":"10.1016\/j.vaccine.2012.09.032_bib0015","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1586\/erv.10.141","article-title":"Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A(H1N1) vaccine","volume":"9","author":"Walker","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2012.09.032_bib0020","unstructured":"ECDC. Q&A for health professionals on vaccines and vaccination in relation to the 2009 influenza A(H1N1) pandemic. Available at: http:\/\/ecdc.europa.eu\/en\/healthtopics\/documents\/0911_pandemic_influenza_(h1n1)_qa_on_vaccines_and_vaccination_experts.pdf [accessed 11.01.12]."},{"key":"10.1016\/j.vaccine.2012.09.032_bib0025","unstructured":"European Medicines Agency. European public assessment reports. Available at: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/landing\/epar_search.jsp&mid=WC0b01ac058001d124 [accessed 11.01.12]."},{"key":"10.1016\/j.vaccine.2012.09.032_bib0030","unstructured":"CHMP recommendations for the pharmacovigilance plan as part of the risk management plan to be submitted with the marketing authorisation application for a pandemic influenza vaccine. EMEA\/359381\/2009 rev. 1.1. http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/Report\/2010\/01\/WC500051739.pdf [accessed 18.07.12]."},{"key":"10.1016\/j.vaccine.2012.09.032_bib0035","unstructured":"European strategy for Influenza A\/H1N1 vaccine benefit-risk monitoring. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2010\/01\/WC500044933.pdf [accessed 18.07.12]."},{"issue":"6","key":"10.1016\/j.vaccine.2012.09.032_bib0040","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2515\/therapie\/2010069","article-title":"Safety review: squalene and thimerosal in vaccines","volume":"65","author":"Montana","year":"2010","journal-title":"Therapie"},{"issue":"11","key":"10.1016\/j.vaccine.2012.09.032_bib0045","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/jama.2011.283","article-title":"Influenza vaccine makers seek ways to speed production, boost effectiveness","volume":"305","author":"Kuehn","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2012.09.032_bib0050","doi-asserted-by":"crossref","first-page":"d3908","DOI":"10.1136\/bmj.d3908","article-title":"VAESCO-GBS Case\u2013Control Study Group. Guillain-Barre syndrome and adjuvanted pandemic influenza A(H1N1) 2009 vaccine: multinational case\u2013control study in Europe","volume":"343","author":"Dieleman","year":"2011","journal-title":"BMJ"},{"issue":"45","key":"10.1016\/j.vaccine.2012.09.032_bib0055","doi-asserted-by":"crossref","first-page":"7878","DOI":"10.1016\/j.vaccine.2011.08.069","article-title":"Guillain-Barr\u00e9 syndrome and H1N1 (2009) pandemic influenza vaccination using an AS03 adjuvanted vaccine in the United Kingdom: self-controlled case series","volume":"29","author":"Andrews","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2012.09.032_bib0060","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/aje\/kwr072","article-title":"Guillain-Barre syndrome, influenza like illnesses, and influenza vaccination during seasons with and without circulating A\/H1N1 viruses","volume":"174","author":"Grimaldi-Bensouda","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"2","key":"10.1016\/j.vaccine.2012.09.032_bib0065","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2012.7342","article-title":"Risk of Guillain-Barr\u00e9 syndrome following H1N1 influenza vaccination in Quebec","volume":"308","author":"De Wals","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2012.09.032_bib0070","doi-asserted-by":"crossref","first-page":"d5956","DOI":"10.1136\/bmj.d5956","article-title":"Neurological and autoimmune disorders after vaccination against pandemic influenza A(H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden","volume":"343","author":"Bardage","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2012.09.032_bib0075","unstructured":"European Medicines Agency. EudraVigilance. http:\/\/eudravigilance.ema.europa.eu\/human\/index.asp [accessed 11.01.12]."},{"key":"10.1016\/j.vaccine.2012.09.032_bib0080","unstructured":"Regulation (EC) No. 726\/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal product for human and veterinary use and establishing a European Medicines Agency."},{"key":"10.1016\/j.vaccine.2012.09.032_bib0085","unstructured":"Directive 2001\/83\/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use."},{"key":"10.1016\/j.vaccine.2012.09.032_bib0090","unstructured":"World Health Organisation Causality assessment for adverse events following immunisation (AEFI). www.who.int\/vaccines-documents\/DocsPDF05\/815.pdf [accessed 16.05.11]."},{"key":"10.1016\/j.vaccine.2012.09.032_bib0095","unstructured":"https:\/\/brightoncollaboration.org\/public\/what-we-do\/standards\/case-definitions\/available-definitions.html [accessed 16.05.11]."},{"issue":"26","key":"10.1016\/j.vaccine.2012.09.032_bib0100","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1016\/j.vaccine.2011.04.005","article-title":"Safety monitoring of Influenza A\/H1N1 pandemic vaccines in EudraVigilance","volume":"29","author":"Kurz","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.09.032_bib0105","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJM200102013440501","article-title":"Vaccinations and the risk of relapse in multiple sclerosis","volume":"344","author":"Confavreux","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2012.09.032_bib0110","doi-asserted-by":"crossref","first-page":"d4159","DOI":"10.1136\/bmj.d4159","article-title":"Safety of adjuvanted pandemic influenza A(H1N1) 2009 vaccines","volume":"343","author":"DeStefano","year":"2011","journal-title":"BMJ"},{"issue":"48","key":"10.1016\/j.vaccine.2012.09.032_bib0115","first-page":"1351","article-title":"Safety of Influenza A(H1N1) 2009 monovalent vaccines \u2013 United States, October 1\u2013November 24, 2009","volume":"58","year":"2009","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"21","key":"10.1016\/j.vaccine.2012.09.032_bib0120","first-page":"657","article-title":"Preliminary results: surveillance for Guillain-Barre syndrome after receipt of influenza A(H1N1) 2009 monovalent vaccine \u2013 United States, 2009\u20132010","volume":"59","author":"Centers for Disease Control, Prevention (CDC)","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"44","key":"10.1016\/j.vaccine.2012.09.032_bib0125","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1016\/j.vaccine.2010.08.069","article-title":"Design of a robust infrastructure to monitor the safety of the pandemic A(H1N1) 2009 vaccination program in Taiwan","volume":"28","author":"Huang","year":"2010","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2012.09.032_bib0130","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amepre.2011.04.004","article-title":"H1N1 and seasonal influenza vaccine safety in the Vaccine Safety Datalink Project","volume":"41","author":"Lee","year":"2011","journal-title":"Am J Prev Med"},{"issue":"14","key":"10.1016\/j.vaccine.2012.09.032_bib0135","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1016\/j.vaccine.2011.01.056","article-title":"Adverse events following pandemic influenza vaccine Pandemrix\u00ae reported in the French military forces\u20142009\u20132010","volume":"29","author":"Mayet","year":"2011","journal-title":"Vaccine"},{"issue":"25","key":"10.1016\/j.vaccine.2012.09.032_bib0140","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1006736","article-title":"Safety and effectiveness of a 2009 H1N1 vaccine in Beijing","volume":"363","author":"Wu","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2012.09.032_bib0145","doi-asserted-by":"crossref","first-page":"539","DOI":"10.4161\/hv.7.5.14821","article-title":"Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations","volume":"7","author":"Banzhoff","year":"2011","journal-title":"Hum vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2012.09.032_bib0150","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00228-010-0961-8","article-title":"Safety surveillance of influenza A(H1N1)v monovalent vaccines during the 2009\u20132010 mass vaccination campaign in France","volume":"67","author":"Caillet","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.vaccine.2012.09.032_bib0155","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1016\/j.vaccine.2011.01.007","article-title":"Guillain-Barre syndrome following receipt of influenza A(H1N1) 2009 monovalent vaccine in Korea with an emphasis on Brighton Collaboration case definition","volume":"29","author":"Choe","year":"2011","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2012.09.032_bib0160","first-page":"121","article-title":"Australian experience with non-adjuvant H1N1 vaccine (Panvax and Panvax Junior)","volume":"33","author":"Cook","year":"2010","journal-title":"Aust Prescr"},{"issue":"7","key":"10.1016\/j.vaccine.2012.09.032_bib0165","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1056\/NEJMoa1008553","article-title":"Safety of influenza A(H1N1) vaccine in postmarketing surveillance in China","volume":"364","author":"Liang","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.vaccine.2012.09.032_bib0170","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.2165\/11539270-000000000-00000","article-title":"Monitoring adverse events of the vaccination campaign against influenza A(H1N1) in the Netherlands","volume":"33","author":"Van Puijenbroek","year":"2010","journal-title":"Drug Saf"},{"issue":"45","key":"10.1016\/j.vaccine.2012.09.032_bib0175","doi-asserted-by":"crossref","first-page":"7248","DOI":"10.1016\/j.vaccine.2010.09.021","article-title":"Adverse events following influenza A(H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009\u2013January 31, 2010","volume":"28","author":"Vellozzi","year":"2010","journal-title":"Vaccine"},{"issue":"7\u20138","key":"10.1016\/j.vaccine.2012.09.032_bib0180","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1345\/aph.1P078","article-title":"Guillain-Barre syndrome following H1N1 immunization in a pediatric patient","volume":"44","author":"Tremblay","year":"2010","journal-title":"Ann Pharmacother"},{"issue":"8","key":"10.1016\/j.vaccine.2012.09.032_bib0185","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s00415-011-5944-x","article-title":"Relapse risk in patients with multiple sclerosis after H1N1 vaccination, with or without seasonal influenza vaccination","volume":"258","author":"McNicholas","year":"2011","journal-title":"J Neurol"},{"issue":"6","key":"10.1016\/j.vaccine.2012.09.032_bib0190","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/ard.2011.150250","article-title":"Immunogenicity and safety of the 2009 non-adjuvanted influenza A\/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases","volume":"70","author":"Saad","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"20","key":"10.1016\/j.vaccine.2012.09.032_bib0195","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1016\/j.vaccine.2011.02.097","article-title":"Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination","volume":"29","author":"Parretta","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.09.032_bib0200","first-page":"65","article-title":"Shoenfeld's syndrome after pandemic Influenza A\/H1N1 vaccination","volume":"1","author":"Barros","year":"2011","journal-title":"Acta Reumatol Port"},{"issue":"24","key":"10.1016\/j.vaccine.2012.09.032_bib0205","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1212\/WNL.0b013e3182020307","article-title":"Acute encephalomyelitis syndromes associated with H1N1 09 influenza vaccination","volume":"75","author":"Denholm","year":"2010","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.vaccine.2012.09.032_bib0210","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/15569527.2010.536797","article-title":"Acute hemorrhagic edema of childhood after H1N1 immunization","volume":"30","author":"Ferreira","year":"2011","journal-title":"Cutan Ocul Toxicol"},{"issue":"19","key":"10.1016\/j.vaccine.2012.09.032_bib0215","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.2169\/internalmedicine.49.4113","article-title":"Cutaneous vasculitis following influenza vaccination","volume":"49","author":"Liu","year":"2010","journal-title":"Intern Med"},{"issue":"3","key":"10.1016\/j.vaccine.2012.09.032_bib0220","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jbspin.2011.02.007","article-title":"Acute polyarthritis after influenza A(H1N1) immunization","volume":"78","author":"Tabache","year":"2011","journal-title":"Joint Bone Spine"},{"issue":"6","key":"10.1016\/j.vaccine.2012.09.032_bib0225","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.vaccine.2010.12.008","article-title":"Spontaneous reporting of adverse events following immunisation against pandemic influenza in Denmark November 2009\u2013March2010","volume":"29","author":"Folkenberg","year":"2011","journal-title":"Vaccine"},{"issue":"33","key":"10.1016\/j.vaccine.2012.09.032_bib0230","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1016\/j.vaccine.2010.05.066","article-title":"National Institute of Public Health Slovenia, Trubarjeva 2, 1000 Ljubljana, Slovenia. Surveillance of adverse events following immunization against pandemic influenza in Slovenia in season 2009\/10","volume":"28","author":"Kraigher","year":"2010","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12013436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12013436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T14:25:49Z","timestamp":1542723949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12013436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":46,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0264410X12013436"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.09.032","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}